Investigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19

Phase 3

Recruiting

• Conditions: COVID-19.; Covid-19; U07.1

• Registration Number: IRCT20080901001165N52
• Lead Sponsor: Bagheiat-allah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation.
The patient has written consciously and freely consent to participate in the study;
The patient has moderate to severe Corona-Virus associated pneumonia;
In the first 48 hours of hospitalization, the patient did not show an improving trend;
In the first 48 hours after his/her inclusion into this study, there is no possibility of discharge from the patient's hospital;

Exclusion Criteria

History of hypersensitivity reaction to glucocorticoids;
Recent hospitalization and treatment history due to COVID-19;
Receive antiviral drugs before including into this study, such as: Hydroxychloroquine, Kaletra, Ribavirin, Oseltamivir;
Receiving Methylprednisolone pulse before including into this study;
Uncontrolled severe chronic illnesses, including heart failure, kidney failure, liver failure, active cancer (history of chemotherapy within recent month), diabetes;
Receiving immunosuppressing /immunomodulating agents, such as systemic glucocorticoids.
Pregnancy;
Lactation.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
eed to receive ICU service (occurrence of shock, resistant hypoxemia despite receiving oxygen via reservoir oxygen mask, GCS score drops below 12). Timepoint: The patient is monitored every 6 hours, but the results are recorded daily in the checklist. Method of measurement: Physical assessment.